Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120


Adipocytes contribute to resistance of human melanoma cells to chemotherapy and targeted therapy.

Chi M, Chen J, Ye Y, Tseng HY, Lai F, Tay KH, Jin L, Guo ST, Jiang CC, Zhang XD.

Curr Med Chem. 2014 Apr;21(10):1255-67.


Leptin reverts pro-apoptotic and antiproliferative effects of α-linolenic acids in BCR-ABL positive leukemic cells: involvement of PI3K pathway.

Beaulieu A, Poncin G, Belaid-Choucair Z, Humblet C, Bogdanovic G, Lognay G, Boniver J, Defresne MP.

PLoS One. 2011;6(10):e25651. doi: 10.1371/journal.pone.0025651. Epub 2011 Oct 3.


Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, Martelli AM.

J Cell Physiol. 2011 Nov;226(11):2762-81. doi: 10.1002/jcp.22647. Review.


Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.

Zhang HR, Chen JM, Zeng ZY, Que WZ.

J Int Med Res. 2013 Jun;41(3):584-95. doi: 10.1177/0300060513480920. Epub 2013 Apr 15.


Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.

Chen C, Chang YC, Lan MS, Breslin M.

Int J Oncol. 2013 Mar;42(3):1113-9. doi: 10.3892/ijo.2013.1789. Epub 2013 Jan 23.


Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells.

Gao J, Tian J, Lv Y, Shi F, Kong F, Shi H, Zhao L.

Cancer Sci. 2009 Mar;100(3):389-95. doi: 10.1111/j.1349-7006.2008.01053.x. Epub 2008 Dec 16.


Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway.

Wang Y, Chen L, Huang G, He D, He J, Xu W, Zou C, Zong F, Li Y, Chen B, Wu S, Zhao W, Wu J.

PLoS One. 2013;8(2):e57391. doi: 10.1371/journal.pone.0057391. Epub 2013 Feb 21.


Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.

Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H.

J Hematol Oncol. 2012 Jul 11;5:16. doi: 10.1186/1756-8722-5-16.


Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways.

Cheng SP, Yin PH, Hsu YC, Chang YC, Huang SY, Lee JJ, Chi CW.

Oncol Rep. 2011 Nov;26(5):1265-71. doi: 10.3892/or.2011.1388. Epub 2011 Jul 12.


Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.

Nomura T, Yamasaki M, Hirai K, Inoue T, Sato R, Matsuura K, Moriyama M, Sato F, Mimata H.

Mol Cancer. 2013 Apr 8;12:27. doi: 10.1186/1476-4598-12-27.


Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.

Dumble M, Crouthamel MC, Zhang SY, Schaber M, Levy D, Robell K, Liu Q, Figueroa DJ, Minthorn EA, Seefeld MA, Rouse MB, Rabindran SK, Heerding DA, Kumar R.

PLoS One. 2014 Jun 30;9(6):e100880. doi: 10.1371/journal.pone.0100880. eCollection 2014.


PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.

Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A.

Cell Signal. 2010 Sep;22(9):1369-78. doi: 10.1016/j.cellsig.2010.05.006. Epub 2010 May 12.


Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.

Block M, Gründker C, Fister S, Kubin J, Wilkens L, Mueller MD, Hemmerlein B, Emons G, Günthert AR.

Int J Oncol. 2012 Nov;41(5):1845-54. doi: 10.3892/ijo.2012.1591. Epub 2012 Aug 21.


Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication.

Uddin S, Bavi PP, Hussain AR, Alsbeih G, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Ahmed M, Al-Kuraya KS.

Carcinogenesis. 2009 Nov;30(11):1832-40. doi: 10.1093/carcin/bgp145. Epub 2009 Jun 11.


NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway.

Chen TJ, Zhou YF, Ning JJ, Yang T, Ren H, Li Y, Zhang S, Chen MW.

Cell Physiol Biochem. 2015;36(3):893-906. doi: 10.1159/000430264. Epub 2015 Jun 9.


Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis.

Jiang CC, Chen LH, Gillespie S, Wang YF, Kiejda KA, Zhang XD, Hersey P.

Cancer Res. 2007 Oct 15;67(20):9750-61.


Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma.

Uddin S, Bavi P, Siraj AK, Ahmed M, Al-Rasheed M, Hussain AR, Ahmed M, Amin T, Alzahrani A, Al-Dayel F, Abubaker J, Bu R, Al-Kuraya KS.

Endocr Relat Cancer. 2010 Feb 18;17(1):191-202. doi: 10.1677/ERC-09-0153. Print 2010 Mar.


[Synergistic effect of targeted inhibition of MEK/ERK and PI3K/AKT survival signaling pathways on induction of apoptosis in melanoma].

Wang XY, Cheng Y, Du JP, Chen DG, Yang XS, Yang ZM, Huang N.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2014 May;45(3):355-61. Chinese.


Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.

Uddin S, Bu R, Ahmed M, Hussain AR, Ajarim D, Al-Dayel F, Bavi P, Al-kuraya KS.

Leuk Lymphoma. 2010 Jul;51(7):1305-14. doi: 10.3109/10428191003802365.


Supplemental Content

Support Center